NCT03301636View on ClinicalTrials.gov

A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 8, 2017

Primary Completion Date

October 21, 2019

Study Completion Date

November 4, 2019

Conditions
Melanoma
Interventions
DRUG

Pembrolizumab

Pembrolizumab will be administered intravenously every 3 weeks starting on day 1.

DRUG

Nivolumab

Nivolumab will be administered intravenously every 2 weeks starting on day 1.

DRUG

Indoximod

Indoximod will be administered orally every 12 hours starting at Day 1

Trial Locations (4)

52242

University of Iowa Hospital and Clinics, Iowa City

55905

Mayo Clinic - Rochester, Rochester

84102

Utah Cancer Specialists, Salt Lake City

87102

University of New Mexico Comprehensive Cancer Center, Albuquerque

Sponsors
All Listed Sponsors
lead

NewLink Genetics Corporation

INDUSTRY

NCT03301636 - A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma | Biotech Hunter | Biotech Hunter